The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease uncontrolled with ...

Anne Wojcicki, co-founder and former CEO of 23andMe, has bid to buy back the genetic testing platform, which was pronounced ...

Clarius Group LLC upped its Regeneron stake by 82.1% last quarter, gobbling up 509 extra shares like they were on clearance.

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently conducted its Annual General Meeting, resulting in approved changes to its company bylaws. The amendments, along with the promising results from ...

Annual Shareholders Meeting was a governance-heavy affair, with proposals flying faster than a biotech merger rumor.